Platelet calpain has many platelet substrates, including external membrane proteins. We thus investigated whether platelet calpain II was associated with platelet membranes in unstimulated and thrombin-activated platelets. A monospecific, goat polyclonal antibody was reared to purified platelet calpain II. Sixteen whole platelet lysates were found to contain 4.5 f 0.7 pg calpain antigen II per 10' platelets (mean & SEMI as determined by a competitive enzyme-linked immunosorbent assay. Using the dipeptide fluorogenic substrate, Suc-Leu-Tyr-MCA, 17 human platelet lysates contained 3.6 & 0.4 pg calpain activity per 10' platelets. Platelet calpain II was associated with the Triton X-lo0 insoluble platelet cytoskeletons from both unstimulated and thrombin-activated platelets. When compared with the total cell content of platelet calpain II, calpain antigen (10% to 13%) and calpain activity (24% to 28%) was associated with platelet cytoskeletons in unstimulated and thrombin-activated platelets, respectively. On immunoblot, the heavy chain (80 Kd) of calpain II was detected in platelet cytoskeletons. Subcellular fractionation studies on both unstimulated and thrombin-activated platelets, revealed that half of the total platelet calpain II antigen was HE CALCIUM-ACTIVATED neutral proteases T (CANP) or calpains I and I1 are ubiquitously distributed, intracellular cysteine proteases whose functions have yet to be fully characterized. The substrate specificities of calpain I and calpain I1 are similar, but the former hydrolyzes its substrates at Ca++ concentrations of 1 to 10 pmol/L, while the latter requires 0.1 to 1 mmol/L. Most purifications of calpains are begun by obtaining the cytosolic fraction (100,OOOg supernatant) of the cell of interest. However, much evidence has accumulated that calpains are associated with cell membranes. In brain, calpain is mostly associated with myelin,' the membrane component of the neuron. Calpain participates in membrane fusion of rat erythrocyte^.^-^ Calpain I1 is involved in mitotic spindle f~r m a t i o n .~ Platelet calpain also has a number of platelet cytoskeleton and membrane substrates, such as talin,6 actinbinding protein,' glycoprotein Ib,8.9 and a membrane protein, aggregin (1 00 Kd)." Thrombin-induced platelet aggregation occurs through calpain, which when activated, cleaves aggregin and unmasks fibrinogen receptors." Recent studies indicate that high and low molecular weight kininogen, which are the most potent calpain inhibitors in plasma," are able to inhibit thrombin-induced platelet aggregation.'*.I3 One way in which kininogens could inhibit thrombin-induced platelet aggregation is through inhibition of platelet calpain. Since high and low molecular weight kininogens can bind to plateletsI3-l5 but are not transported into platelets,16 kininogens could only inhibit calpain if both become expressed on the external membrane of platelets. In this investigation, we sought to determine if platelet calpain is associated with platelet cytoskeletons and membranes and if any platelet calpain is externalized on the platelet membrane after activation. associated with cytosol, and the other half was associated with the membrane fraction. Platelet calpain II was not seen on the surface of unstimulated, paraformaldehyde fixed platelets by immunofluorescence. However, on thrombin-activated platelets, rim immunofluorescence was seen, indicating that activated platelets externalize their calpain. This observation was confirmed by the finding that about 2.000 molecules per platelet of an '261-anti-calpain II Fab' specifically bound to thrombin-activated but not unstimulated platelets. Both dibucaine (1 mmol/L) and platelet activating factor (1.86 pmollL) in the absence of external Ca", but not collagen (5 pg/mL) or ionophore A23187 (2.5 pmol/L) in the absence of external Ca++, were also able to externalize platelet calpain II antigen, as indicated by a similar level of specific '261-anti-calpain ll Fab'-platelet binding. These combined studies indicate ttiat platelet calpain II is a major protein, comprising 2% of total platelet protein, a substantial portion of which is membraneassociated. When platelets are activated by thrombin and platelet activating factor, calpain II antigen also becomes present on the external platelet surface.
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METHODS
Ionophore #A23187 was purchased from Calbiochem, Behring Diagnostics, San Diego, CA. Platelet activating factor (PAR 1-0-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine) was generously provided by Dr A. Koneti Rao, Temple University (Philadelphia, PA). Acid soluble collagen was obtained from HormonChemie, Munich, West Germany. '*'I-NaI (50 mCi/mmol) was purchased from ICN Pharmaceuticals, Irvine, CA. Iodogen chloroamide, 1,3,4,6-tetrachloro-3a-6a-diphenylglycluril, was obtained from Pierce Chemical Co, Rockford, IL. Nitrocellulose paper, high and low molecular weight standards for sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and dithiothreitol (DTT) were purchased from Bio-Rad Corp, Richmond, CA. Apiezion oil was obtained from Apiezion Products Limited, London, England. N-butyl-phthalate was obtained from Fisher Scientific Co, King of Prussia, PA. Affinity-purified rabbit anti-goat F(ab)', antibody adsorbed with normal human serum, which was to be iodinated and used as a second antibody, was purchased from Pel-Freez, Rogers, AR. Suc-Leu-Try-MCA (N-Succinyl-Leu-Tyr-7-Amido-4-methylcoumarin) was obtained from Sigma Chemical Co, St Louis, MO. Human a-thrombin (3,205 U/mg) was the generous gift of Dr John Fenton, New York State Department of Health, Albany, NY. All other reagents were obtained from Sigma and were the best reagent grade.
Human platelet calpain I1 was purified by polyethylene glycol precipitation, ion exchange chromatography on DE-52, chromatography on reactive red agarose and gel filtration on Ultrogel AcA (LKB Instruments, Rockville, MD) as previously reported." During the purification, calpain activity was monitored by an a-casein assay. One unit of the enzyme is defined as the amount of enzyme that caused an increase of 1.000 absorbance unit/h/mL at 280 nm in the caseinolytic assay. Either purified calpain I1 or calpain in platelet lysates was assayed using the fluorogenic substrate, Suc-Leu-Tyr-MCA, as previously reported.17 The purified calpain I1 was analyzed on reduced SDS-PAGE performed by the procedure of Laemmli.'* Immunochemical reagents and assays. An anti-platelet calpain I1 antiserum was raised in goats. Purified platelet calpain I1 (500 pg) was inactivated with EDTA (2 mmol/L) and leupeptin (1 mmol/L) and injected intramuscularly with complete Freund's adjuvant. Three weeks after the initial injection, an intramuscular booster injection (250 pg) in complete Freund's adjuvant was given. One week later, the goat was bled, and serum was obtained. Immunoblots using this antiserum were performed by a modified technique" of Towbin et
On all immunobiots, blocking of the nitrocellulose from nonspecific protein adsorption was performed with "Blotto."20 In each immunoblot study the polyclonal anti-platelet calpain I1 antiserum was used as the primary antibody, and a I2'I-rabbit anti-goat antibody was used as the second antibody. The rabbit anti-goat antibody was radiolabeled with I2'I using Iodogen by a procedure similar to that used to radiolabel purified high molecular weight kinin~gen.".'~ The immunoblot was detected by autoradiography after 24 to 72 hours exposure of Cronex I1 film (E.I. Du Pont and Nemours Co, Wilmington, DE) to the nitrocellulose.
Antibody from the goat anti-platelet calpain I1 antiserum was purified by the MAPS Protein A affinity chromatography (Bio-Rad Corp, Richmond, CA). F(ab)', of the anti-calpain I1 antibody were prepared by incubation of 10 mg IgG with pepsin (0.2 mg) in 0.1 mol/L acetate buffer, pH 4.5 for 24 hours.2' The reaction was stopped by raising the pH to 8.0 with 2.5 mol/L Tris base. The F(ab)', were separated from the Fc portion by affinity chromatography over Protein A. Fab' were made from the above fragments by reduction with 12 mmol/L 8-mercaptoethanol followed by alkylation with 50 mmol/L iodoacetamide in the dark. Purified antiplatelet calpain I1 antibody and Fab' were radiolabeled with '*'I using Iodogen as previously r e p~r t e d . '~. '~ A competitive enzyme-linked immunosorbent assay (CELISA) to measure platelet calpain I1 antigen was developed. This assay was performed as previously reported for high molecular weight kininogen.I6 Briefly, on the first day, purified platelet calpain 11 antigen in 0.01 mol/L Na,CO,, pH 9.6 was linked to polystyrene cuvette wells by incubation overnight at 37°C. On the same day, purified calpain I1 antigen for the standard curve or platelet material (lysates, cytoskeletons, or subcellular fractions) were incubated overnight also at 37OC with a previously optimally titered antiserum for the assay. The amount of purified calpain I1 used to link to cuvette wells and in the standard curve was determined by functional and protein assays. One unit of calpain I1 activity was equal to 10 pg pure calpain I1 antigen." Protein determination was performed by
Proteins.
the assay of Bradford using crystalline bovine serum albumin (BSA) as the standard.z2 On the second day, the cuvette wells were washed with 0.01 mol/L Na,PO,, 0.15 mol/L NaCI, pH 7.4 containing 0.05% phosphate-buffered saline Tween-20 (PBS-Tween). After blocking the cuvette wells with 0.2% radioimmunoassay-grade BSA, each overnight incubation mixture was added to a designated cuvette well for a 2-hour incubation. After washing the cuvette wells with PBS-Tween, rabbit anti-goat antibody conjugated with alkaline phosphatase was added. After a further 2-hour incubation and cuvette washing, the conjugated antibody bound to the wells was detected by the addition of p-nitrophenylphosphate (Img/mL) in 0.05 mol/L Na2C0,, 1 mmol/L MgCl,, pH 9.8. A computer program was used to calculate the results2' as previously reported.I6
Platelet-rich plasma24 was obtained from citrated human blood and gel-filtered on Sepharose 2B: ' equilibrated in calcium-free Tyrode's buffer (0.135 mol/L NaCI, 2.7 mmol/L KCl, 11.9 mmol/L NaHCO,, 0.36 mmol/L NaH2P0,, pH 7.35) with magnesium (1 mmol/L), HEPES (14.7 mmol/L), BSA (1 mg/mL), and dextrose (3.5 mg/mL).26 Henceforth, this buffer will be referred to as HEPES-Tyrode's. Only gel-filtered platelets were used for the 12'I-anti-platelet calpain Fab' binding studies. Unstimulated gel-filtered platelets used in the content/localization studies of calpain I1 were pooled and then treated for 30 minutes at 37OC with metabolicinhibitors antimycin A (15 pg/mL), 2-deoxy-Dglucose (30 mmol/L), and D-gluconic acid 8-lactone (10 mmol/L) and then pelleted by centrifugation. Metabolic inhibitors were used in order to prevent the platelets from clumping during the centrifugations. Washed platelets for the determination of the content/ localization studies of platelet calpain I1 were also prepared by the centrifugation technique of Mustard et al,27 performed as previously reported." Using either technique, the final washed platelets for calpain I1 content/localization studies were suspended in 0.05 mol/L Tris-C1, 0.15 mol/L NaCl, pH 7.4 containing 5 mmol/L DTT, and 5 mmol/L EDTA. Platelet calpain I1 activity was quantified by fluorogenic assay in 10,OOOg supernatants of sonicated platelets; platelet calpain I1 antigen was quantified by CELISA in Triton X-100 (0.5%) solubilized whole platelets.
Platelet cytoskeletons were made by treatment of either unstimulated or thrombin-activated platelets (0.1 to 0.5 U/mL) with 0.5% Triton X-100 followed by centrifugation at 100,000g for 2 hours at 4OC. The cytoskeleton is defined as the Triton insoluble pellet after 100,OOOg ultracentrifugation. The Triton X-100 insoluble pellet for assay was resuspended to its original volume in buffer containing Triton X-100. Previous studies indicated that 0.5% Triton X-100 did not interfere with the fluorogenic or immunochemical assays for calpain. 16 When studies were performed on thrombin-activated platelets, the platelets were pretreated with 1 mmol/L Gly-Pro-ArgPro to prevent fibrin formation.28
Platelet subcellular fractions were prepared from sonicated, washed platelets. Sonication was performed with Model W225 R Sonicator (Heat Systems Ultrasonics, Plainview, NY) for five-20 second periods while the platelets were kept on ice. Sonicated platelets were initially centrifuged at 10,OOOg for 10 minutes to pellet unlysed platelets, large fragments, granules, and mitochondria. The supernatant of the 10,OOOg centrifugation was then applied to an ultracentrifuge for centrifugation at 100,OOOg for 2 hours at 4OC. The supernatant of this centrifugation was the cytosolic fraction; the pellet contained the platelet membranes. For assay, the membranes were resuspended in buffer containing 0.5% Triton X-100 to the original volume of the 10,OOOg supernatant. When distribution studies of calpain were performed with platelet cytoskeleton or subcellular fractions, evaluations were done only on samples in which total enzyme recovery by totaling the parts of activity and/or antigen measurements was at least 70% of the total.
Preparation of platelets.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From lmmunopuorescence ojplarelets. Immunofluorescence staining of unstimulated and thrombin-activated platelets was pefonned by the technique of Wencel-Drake et aLm Gel-filtered platelets were left untreated or werestimulated with 0.1 U/mL thrombin for 5 minutes in the presence of Gly-Pro-Arg-Pro ( I mmol/L).'* Aliquots of each platelet preparation were fixed with 2% paraformaldehydeon ice for 1 hour. Unreacted aldehyde was blocked with 0.005 mol/L NH,CI. 0.01 mol/L Tris 0.15 mol/L NaCI. pH 7.4, and the cells were permitted to settle on polylysine-mated glass coverslip. In some cam. the cells were treated with 0.1% Triton X-100 for 3 minutes to render them permeable to antibody before staining. The permeable or intact cells were then incubated for 20 minutes with either specific antibody or preimmune goat serum. The cells were rinsed with 0.01 mol/L Tris. 0.1 5 mol/L NaCI. pH 7.4 containing 0.1% radioimmunoassay grade BSA and stained for 20 minutes with a fluoresceinlabeled rabbit anti-goat or goat anti-rabbit IgG (Sigma). The platelets were viewed at a magnification of 400x with an Olympus BH2 microscope (Olympus Corp. New Hyde Park, NY) equippad with a 100-W mercury burner for phasecontrast and epifluorescence microscopy with a chromatic splitter and 0515 barrier filter for photography using 3M IS0 IO00 film. Identical photographic exposure, development. and printing times were used to depict immune and nonimmune (control) immunofluorescence. Antiserum to the PADGEM proteinm.'' was the generous gift of Drs Barbara Furie and Cindy Rerman. New England Medical Center, Boston,
MA.
The PADGEM protein is a platelet a-granule membrane protein that only becomes expressed on the external membrane of activated platelets."."
Plareler binding studies. '*'I-anti-platelet calpain II Fab'-platelet binding studies were performed with unstimulated and agonist-stimulated gel-filtered platelets in HEPES-Tyrode's buffer. Thrombin(0.5 U/mL).dibucaine(l mmol/L). PAF( 1.86pmol/L). collagen ( 5 pg/mL), and ionophore A23187 (2.5 pmol/L) were the agonists used in t h w experiments. In all binding experiments. platelets were at a final concentration of at least 2 x !@/mL. In a typical binding experiment. platelets were preincubated I hour at 37OC with or without agonist and in the absence or presence of 0.6 pmol/L purified goat anti-human platelet calpain II antibody. The bindingstudy was then initiated upon theadditionof 1.8 to9 nmol/L '"I-anti-platelet calpain I1 Fab' (final concentration. 1 to 8 pCi/pg) to platelet samples that were pretreated or not with agonist in the absence or presence of unlabeled goat anti-human platelet calpain 11 antibody. At each time point ( 5 to 210 minutes) after the addition of the radiolabeled Fab'. three 50 pL aliquots of the platelets were placed on a 200 pL mixture of silicon oils ( 1 part Apiezion/9 parts N-butyl phthalate) in polypropylene microsediment tubes with narrow bore extended tips (Santedt. Inc. Princeton. NJ) for centrifugation in a microluge (Model B: Beckman Instruments. Fullerton. CA) at 9.650~ for 2 minutes at mom temperature. After the supernatant was carefully removed. the tips containing the pellet were amputated and counted in a y-counter. The percent of the radioligand bound was determined by the ratio of the counts in the amputated tip with three 50 pL unspun samples. In these experiments spccific binding of the "'I-Fab' to unstimulated and agonistactivated platelets was determined by subtracting nonspecific binding (binding determined in the presence of 0.6 pmol/L anti-calpain IgG) from total binding. Lactic dehydrogenase assays on the platelet material from these binding experiments were performed by the procedure of Wroblewski and Ladue."
RESULTS

Characterization of anti-calpain antibody.
Purified CANP was shown on SDS-PAGE to consist of two subunits:
one heavily staining at 80 Kd and one lightly staining at 30 Kd (Fig I , left lane) . When this antigen was inactivated with EDTA and leupeptin and then was injected into a goat, a monospecific antiserum to human platelet CANP was produced (Fig 2) . On immunodiKusion, the goat anti-CANP serum gave a single precipitin arc that showed complete immunochemical identity to purified calpain I I antigen and calpain antigen in a whole platelet lysate. This antiserum also showed partial immunochemical identity to calpain antigen in red blood cells and no immunochemical recognition of any antigen in normal human plasma. On immune blot, the goat anti-calpain antiserum recognized only the 80 Kd subunit of purified human platelet calpain I1 (Fig 1. center lane). The specificity of this antiserum was further shown by immunoblot of a whole platelet lysate. This antiserum to human platelet calpain I1 recognized platelet calpain as a single band at 80 Kd in a whole platelet lysate (Fig I , right lane) .
Using purified platelet calpain I I for the standard curve and the goat anti-calpain II antiserum, a CELISA to measure platelet calpain I1 was developed. On this assay equal total amounts of purified platelet calpain 11, platelet calpain in a platelet lysate, or a mixture of pure platelet calpain II and platelet calpain in a cell lysate produced competition inhibition curves that were superimposable (Fig 3) . Moreover, when pure platelet calpain I1 was added to normal plasma that contains a high concentration of calpain inhibitors, such as high and low molecular weight kininogen and a-2-macrogloQuantification of human platelet calpain.
. In the outer wells. PLTS repreaents a Triton X-100 lymte of ld human platelets: CANP, purified platelet wlpain II: RBC. a Triton X-100 lysate of human red blood cells: and NHP. normal human plaama. After formation of the precipitin arca, the agarose was rooked in PBS, dried, and stained with 0.26% Coomassie blue R-250 and 1 % amido block in a solution that consisted of 6 parts methanol. 6 parts water. and 1 part acetk acid.
bulin, the competition inhibition curve was superimposable with that produced by pure calpain I1 alone (data not shown). These studies indicate that the antibody to platelet calpain II equally recognizes its antigen when pure and when present in biologic fluids. The standard curve on the CELISA was linear from IO to 200 ng purified platelet calpain 11. Using the midpoint of the standard curve as a reference, the interassay coeficient of variation with this assay was 20%. The intraassay coefficient of variation of any particular sample was less than 10%. Using the CELISA, platelet calpain I I antigen was measured in 16 platelet lysates. The mean 2 SEM amount of platelet calpain antigen I1 was 4.5 2 0.7 pg/lO" platelets. This value for platelet calpain I1 was independently confirmed by functional studies using the fluorogenic substrate Suc-Leu-Tyr-MCA on I7 different lysates. By functional assay. the mean 2 SEM amount of platelet calpain activity was computed to be 3.6 2 0.4 pg/108 platelets. knowing the specific activity of purified platelet calpain II. When a whole platelet lysate was electrophoresed by SDS-PAGE, a Coomassie blue-stained band at 80 Kd was seen, identical to the migration of the top band at 80 Kd of a partially proteolyzed sample of purified platelet calpain I1 (Fig 4. arrow) .
Characrerizorion of calpain in plareler cyroskelerons. Studies were performed to determine the distribution of platelet calpain 11. Initial investigations sought to determine if human platelet calpain I I was associated with platelet cytoskeletons (Table I ) . Ten percent of platelet calpain antigen I1 and 24% of platelet calpain activity were associated with cytoskeletons of unstimulated platelets. Likewise, 13% of platelet calpain antigen I1 and 28% of platelet calpain activity were associated with the cytoskeletons of thrombinactivated platelets. lmmunoblot of the resuspended platelet cytoskeletons made from unstimulated platelets revealed that human platelet calpain I1 antigen was present in the Triton X-I00 insoluble material, and it was 80 Kd, a size similar to calpain antigen I1 in a whole platelet lysate (Fig 4.  on right) .
Disrriburion of colpain in ploreler subcellular fracrions.
Platelet subcellular localization studies were performed on sonicates of unstimulated and thrombin-activated platelets.
In fractions of unstimulated platelets, 54% of the total platelet calpain 11 was associated with the platelet cytosol; 46% of the total platelet calpain I1 was associated with the membrane fraction (Table 2) . Likewise, the platelet calpain I1 distribution pattern was similar when studies were performed on thrombin-activated platelets. Forty-nine percent of the total platelet calpain I I antigen was localized to the cytosol; 51% of the total platelet calpain I I was localized to platelet membranes. These studies indicate that platelet calpain II is approximately equally distributed between cytosolic and membrane fractions in platelets. Localizarion of plareler calpain ofrer rhrombin-ocrivorion. Although a substantial amount of platelet calpain I1 was associated with the membrane fraction in subcellular fractionation studies. these investigations did not reveal whether the protein was on the internal or external portion of the membrane. Immunofluorescence studies were performed to determine if any calpain antigen I1 can be found on the external surface of platelets (Fig 5) . When platelets were fixed to the coverslip and permeabilized with Triton X-100 t-
CALPAIN ANTIGEN ng ( Fig 5. GAC + TRITON) , calpain I1 antigen, on this immunofluorescent study with the anti-calpain I1 antiserum diluted 1 :200, was homogenously distributed throughout the platelets. This result was expected from a cytosolic protein.
Further investigations were performed to detect any evidence for platelet calpain I1 expression on nonpermeabilized platelets. When unstimulated platelets were reacted with a 150 dilution of the anti-calpain I1 antiserum, there was no specific immunofluorescence. similar to the finding when these same unstimulated platelets were reacted with normal goat serum diluted to the same extent. However, when thrombin-activated platelets were reacted with a 150 dilution of the goat anti-calpain I1 antiserum, there was specific immunofluorescence on the external membrane of the platelets, outlining the pattern of cells seen in the companion phase contrast photograph (Fig 5 ) . The immunofluorescence seen with the anti-calpain II antiserum on thrombin- Platelets were wwhed by gel filtration" or centrifugation.'eAfter being treated with 0.5 U/mL a-thrombin or being Ish untreated, they were solubilized with 0.5% Triton X-100. The cytoskeleton of both unstimulated and thrombirwctivated platelets is defined as the insolubb materiel (pellet) in 0.5% Triton X-100 isdated after centrdugatii at lOO.OOOg for 2 how8 at 4OC. The 100,OOOgsupanatant is tamed cytosol. Celpain activity ww n'108~wed by fluorogenic w w : calpain antigen II. by a CELISA (see "Methods").
*Values represent the m a n of two experiments with simila results.
tvalues r q "
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activated platelets did not result as a nonspecific response to thrombin stimulation. There was no immunofluorescence from thrombin-activated platelets reacted with normal goat serum. The pattern of external membrane immunofluorescence seen with calpain differed from that seen with the membrane expression of the platelet a-granule marker, PADGEM. The PADGEM protein appeared to be homogenously distributed in a rim pattern on the membrane; the platelet calpain I1 appeared to be segmentally distributed in clumps about the external membrane. "'I-anti-platelet calpain I1 Fab' binding to unstimulated and thrombin-activated platelets was performed to confirm the presence of calpain II antigen on the thrombin-activated platelet membrane (Fig 6) . There was no specific binding of the "'I-anti-calpain II Fab' to unstimulated platelets. However, there was specific binding of the "'I-anti-calpain I1 Fab' to thrombin-activated platelets (0.5 U/mL). Binding of the antibody to activated platelets reached equilibrium in 2 hours with about 2,000 to 3,000 Fab' molecules specifically bound per platelet. This value indicated that 37 to 55 ng of calpain antigen per 10' platelets, or about 1% of the total platelet calpain antigen, is expressed on the external membrane of thrombin-activated platelets. Although thrombin Platelets were wwhed by gd filtration" or cenhifugstion.'' Unstimuleted washed platelets were treated with mtebdii inhbiors (see can induce the the external membrane expression of calpain I1 antigen. it did not stimulate platelet calpain I1 secretion. No calpain activity or antigen was detected in the suspension media of thrombin-activated platelets. In the "'I-anticalpain I1 Fab'-platelet binding experiments. the level of lactic dehydrogenase loss was less than 0.5% in all the platelet samples incubated up to 210 minutes after thrombin activation. This value was similar to the level of lactic dehydrogenase loss seen with unstimulated platelets incubated for the same period of time.
The ability to induce specific '*'I-anti+alpain Fab' binding to activated platelets was not a unique response to thrombin stimulation (Fig 7) . Two additional platelet agonists, dibucaine ( 1 mmol/L) and PAF (1.86 pmol/L). stimulated platelets to allow for specific '*'I-anti-caIpain II Fab' binding. Both agonists, similar to thrombin, produced platelet calpain I I exposure such that 1,600 to 3,500 molecules of "'I-anti-calpain I I Fab' bound to the platelet surface after treatment. However, these agonists have different effects on platelets. PAF. like thrombin, allowed for less than 0.5% lactic dehydrogenase loss after 210 minutes of treatment. Alternatively, dibucaine produced 40% lactic dehydrogenase loss after the same period of incubation. Platelet agonists, in general, do not possess the ability to induce calpain I1 antigen exposure. Neither collagen (5 pg/mL) nor ionophore A23187 (2.5 pmol/L) in the absence of external Ca' ' could induce specific "'I-anti-calpain I1 Fab' binding to platelets.
DISCUSSION
The studies reported here indicate that platelet calpain I I is a major platelet protein comprising 2% to 3% of total platelet protein (Fig 4) . This result was predicted by our previous finding" that a purification of only a 100-fold over the platelet cytosol resulted in a homogenous preparation of platelet calpain 11. It was not surprising to find calpain activity and antigen associated with the platelet cytoskeleton, since the enzyme had previously been reported to be associated with cell adhesion plaques! Although IO% to 13% of total calpain antigen I1 was associated with the platelet cytoskeleton, 24% to 28%of the total platelet calpain activity was associated with the cytoskeleton (Table I) . It is possible that the fluorogenic assay for calpain detected some platelet calpain I activity not measured by our antiserum reared to calpain 11. However, our studies suggest that the majority of platelet calpain is calpain 11." Alternatively, the increased calpain activity/antigen ratio with the cytoskeletons suggests that platelet calpain I1 is protected from autolysis and/or from inhibition by its specific inhibitor, calpastatin, when associated with the platelet cytoskeleton. The finding that such substantial amounts of platelet calpain are associated with platelet membranes on subcellular fractionation studies was not expected ( Table 2) . Our results differ from those of Phillips and Jakabova7 and Yoshida et al.33 They found less than 6% calcium activable caseinolytic activity in the 100,OOOg pellet. This difference between their findings and ours cannot be completely explained. There are two possible reasons why we were able to measure membrane-associated calpain activity and they were not. First, our approach to solubilize the platelet membrane with 0.5% Triton X-100 before assay for function may have allowed for detection of full expression of calpain activity. Second, our use of a small mol wt fluorogenic substrate rather than the larger mol wt casein substrate may have also contributed to the detection of calpain activity. Our finding that a large portion of platelet calpain is associated with platelet membrane by activity and antigen determination, however, parallels the finding in brain that a substantial part of brain calpain is associated with myelin, brain tissue membrane.' Previous studies by Samis et a1 indicated that calpain I was not associated with platelet membra ne^.^^ Since they used a monoclonal antibody directed to the large subunit of human red cell calpain I, and since there is only a 62% amino acid sequence homology between the large subunit of calpain I and 11,95 it is possible their antibody did not recognize the platelet calpain I1 epitopes associated with membrane. As shown in Fig 2, our polyclonal antibody to human calpain I1 only partially recognizes the calpain antigen in human red cells, as indicated by the line of partial identity on immunodiffusion. Further, since only calpain I has been shown to be associated with human erythrocyte membranes:6 it is possible that only calpain I1 is associated with platelet membranes.
TIME (min)
Although a large portion of platelet calpain I1 antigen was associated with the membrane fraction, the location of the calpain on the membrane was not clear. Since exogenous kininogens are able to inhibit thrombin-induced platelet activation'*." and since calpain is involved in thrombininduced platelet activation," additional studies were performed to determine if any calpain antigen I1 is expressed on the external membrane of platelets after thrombin-induced platelet activation. The finding that calpain I1 antigen became detectable on the plasma side of the membrane after thrombin-induced platelet activation as seen on immunofluorescence ( Fig 5) indicates that platelet calpain I1 antigen may be externalized upon platelet activation. It is presently unclear whether the source of the externalized calpain I1 is enzyme associated with membrane or cytosol. Recent studies indicate that activated platelets are able to externalize another cytosolic protein, the A subunit of platelet factor
XIII.37.38
In order to directly show that platelet calpain is expressed upon the activated platelet surface, binding of '"I-antiplatelet calpain I1 Fab' to platelets was investigated. The and reacted with '%anti-platelet calpain Fab' (1.8 to 9 nmol/L, final concentration) for the times indicated. After the binding reaction, the total and nonspecific (binding of the radioligand in the presence of a 0.6 pmol/L excess unlabeled goat anti-calpain antibody) level of binding were determined. Nonspecific binding was subtracted from total binding t o obtain specific binding. The data plotted represent specific binding. The specific binding data presented for dibucaine-activated platelets are mean i SEM from five experiments; for PAF-activated platelets, mean i SEM of three experiments; and for both ionophore A23187-and collagen-treated ( 0 ) platelets, the mean of two experiments.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From finding that lZSI-anti-platelet calpain I1 Fab' specifically binds to thrombin-activated but not unstimulated platelets suggests that calpain I1 antigen can be induced to be expressed upon the external surface of the platelet membrane (Fig 6) . In the radiolabeled Fab' binding studies, the 60-to 90-minute incubation time to demonstrate specific binding probably represents the duration of time necessary for the antibody to begin to bind with its antigen. It is unlikely to represent the duration of time necessary for thrombin to stimulate platelets to expose calpain antigen. As shown by the immunofluorescence studies, thrombin treatment of platelets will expose calpain antigen very rapidly. Assuming that one molecule of anti-calpain I1 Fab' (mol wt (Fig 7) . The externalization of some platelet calpain I1 after platelet stimulation may explain how high molecular weight kininogen can inhibit thrombin-induced platelet aggregation by blocking calpain's ability to expose the fibrinogen receptor.'&" Further, it may explain the mechanism of cleavage of glycoprotein Ib in platelets stimulated with dibucaine, since the portion cleaved, glycocalicin, is known to be on the external surface of the The mechanism by which human platelet calpain I1 becomes available after thrombin stimulation on the external membrane of platelets is not known. Since the amount of platelet calpain I1 that is expressed on the activated platelet surface is only 1% of total platelet calpain 11, we cannot exclude the possibility that some cell lysis contributed to the calpain I1 antigen detected. Measurement of lactic dehydrogenase loss during the entire 210 minutes of the Fab' binding experiments to thrombin-and PAF-treated platelets shows that less than 0.5% of total platelet lactic dehydrogenase was lost. However, if cell lysis was a major contributor to the detection of calpain antigen I1 on activated platelets, then dibucaine-treated platelets, which had 40% lactic dehydrogenase loss, should have had the largest amount of I2*I-Fab' binding. The fact that all cell suspensions were centrifuged through an oil gradient, and dibucaine-treated platelets had no more "'I-Fab' binding than thrombin-or PAF-treated platelets, argues against the notion that the calpain I1 antigen detected was merely trapped protein from cell lysis. At present it is not known how thrombin and PAF, a less potent agonist, can induce calpain exposure whereas collagen and A23 187 are unable to do so. Further studies are needed to ascertain the mechanism(s) by which these agonists induce calpain I1 exposure on the external membrane of platelets. Understanding this potential new mechanism for exposure of cellular proteins may be important to recognize the mode of expression of other platelet cytosolic proteins, such as the A subunit of factor XII136*37 and tissue trans- For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
